Expand all sections

Nivolumab

Opdivo

Extended indication Hepatocellular carcinoma after sorafenib (liver cancer)
Therapeutic value No judgement

Product

Active substance Nivolumab
Domain Oncology and Hematology
Main indication Liver cancer
Extended indication Hepatocellular carcinoma after sorafenib (liver cancer)
Proprietary name Opdivo
Manufacturer BMS
Additional remarks Dit betreft een indicatie-uitbreiding. Registratieaanvraag teruggetrokken in september 2017. 'The company stated that despite the promising data shown for Opdivo in the treatment of hepatocellular carcinoma, uncertainties about the design of the main study did not allow the CHMP to conclude that the benefit outweighed the risk at the present time.'

Registration

There is currently nothing known about registration.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.